11 results about "Secondary hyperparathyroidism" patented technology

The present invention relates to a process for the preparation of AMG416. A method for preparing AMG416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is an octa-amino acid selective peptide antagonist of the synthesized calcium-sensitive receptor. It has been developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorders (CKD-MBD).

The present invention relates to a process for the preparation of AMG416. A method for preparing AMG416, or a pharmaceutically acceptable salt thereof, is provided. AMG 416 is an octa-amino acid selective peptide antagonist of the synthesized calcium-sensitive receptor. It has been developed as an intravenous treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients with chronic kidney disease-mineral and bone disorders (CKD-MBD).

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

The invention belongs to the technical field of chemical raw material medicines, and particularly relates to an aryl alkyl amine compound as well as a preparation method and application thereof. The structure of the aryl alkyl amine compound is shown as a formula I. Experiments prove that the allosteric agonist effect of the compound provided by the invention on a calcium-sensitive receptor is superior to or equivalent to that of Evocalpet, and the aryl alkyl amine compound has potential in preparation of drugs for treating secondary hyperparathyroidism. Formula I

The present invention relates to the technical field of Chinese medicine compositions, and in particular to a Chinese medicine composition for treating secondary hyperparathyroidism and a preparation method thereof. Specifically, it is prepared from the following components by mass: 20-26 parts of Cordyceps sinensis, 20-26 parts of Eucommia ulmoides, 18-22 parts of Gecko, 18-22 parts of Cuscuta australis, 15-19 parts of Achyranthes bidentata, 14-18 parts of Peach Kernel, 13-17 parts of Panax notoginseng, 10-14 parts of Olibanum, 10-14 parts of Schisandra chinensis, 8-12 parts of Lotus Seed, 8-12 parts of Licorice, and 4-8 parts of Mulberry. The Chinese medicine composition provided by the present invention has excellent therapeutic effect on secondary hyperparathyroidism, and the patient's blood phosphorus, blood calcium, PTH, Scr, BUN and other indicators are significantly improved.

Methods of preventing or mitigating loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT) are disclosed.

This application relates to the field of intelligent medicine, and particularly relates to a method, system and device for predicting EPH after parathyroidectomy based on images. It includes obtaining parathyroid images of a patient; extracting EPH highly correlated features based on the parathyroid images to predict EPH after surgery to obtain a prediction result; wherein, the construction process of the EPH highly correlated features is as follows: S1: obtaining a parathyroid image set, EPH grouping labels, and blood calcium concentration labels of the patient; S2: extracting primary features from the parathyroid image set based on the EPH grouping labels and blood calcium concentration labels; S3: performing feature screening on the primary features to obtain the EPH highly correlated features. This method predicts whether EPH occurs after parathyroidectomy for patients with secondary hyperparathyroidism through radiomics features, and has good clinical value.

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

Disclosed are methods of preventing or reducing loss of kidney function in a chronic kidney disease (CKD) patient having secondary hyperparathyroidism (SHPT).

Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng / ml and / or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.

To provide a novel vitamin D supplementation method to patients with cancer and patients treated with an agent that increases the risk of hypocalcemia.SOLUTION: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia and / or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and / or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.SELECTED DRAWING: None